Participants
The goal of the 1st part of the workshop was to illustrate the way in which specialist knowledge from different drug development disciplines may be effectively integrated to identify, evaluate and mitigate risks associated with undesirable immunogenicity of therapeutic proteins and peptides.
PARTICIPANTS OF THE 1ST PART OF THE WORKSHOPS 2012:
Companies, institutions |
||
| Ablynx | IBR Inc. | PreClinical Safety (PCS) Consultants Ltd |
| Agennix AG | InflaRx GmbH | Sandoz / Hexal |
| Baxter Innovations GmbH |
Laboratorios De Especialidades Immunologicas S.A De C.V |
SuppreMol GmbH |
| Boehringer Ingelheim Pharma GmbH & Co KG | MAB Discovery GmbH | Swissmedic |
| BSL BIOSERVICE Scientific Laboratories GmbH | Medical Products Agency | synlab Services GmbH |
| CSL Behring GmbH | Merck KGaA | Takeda |
| Dr. Regenold GmbH | Merckle GmbH | Two Hats Regulatory Science GbR |
| Drug Development Licensing Limited | NDA Regulatory Service GmbH. | UCB Celltech |
| F. Hoffmann-La Roche Ltd | Novozymes | University of Regensburg |
Positions |
||
| Assessor / Inspector | Group Leader Immunoanalytics | Scientist |
| Assessor, Dept. Of Pharmaceutics and Biotechnology | Head DRA CMC | Scientist Antibody Technologies |
| Associate Director | Head of Business Development | Senior Assoicate |
|
Board Certified Expert in Pharmacology and Toxicology, Managing Director |
Laboratory Head | Senior Consultant |
| Chief Medical Officer | Manager of Projects and Technical assistance | Senior Manager Regulatory Affairs |
| Clinical and Regulatory Consultant | Manager Regulatory Affairs Biosimilars | Senior Medical Advisor |
| Consultant | Product Manager | Senior RA Biosimilars |
| Director Non-Clinical Development | Regulatory Affairs Manager | Student Master Chemie |
| Director Protein Science | Regulatory Scientist | |
| Expert Scientist | Research Scientist | |
Countries |
||
| Austria | Germany | Switzeland |
| Belgium | Mexico | United Kingdom |
| Denmark | Sweden | |